Potential anti-TNF response biomarker identified

(European League Against Rheumatism) DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies. This data, presented today at the European League Against Rheumatism Annual Congress, bring clinicians a step closer to being able to personalise a patient's treatment pathway.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news